Progress in adaptive immunotherapy for cancer in companion animals: Success on the path to a cure

Veterinary Sciences

Volumn 2, Issue 4, 2015, Pages 363-387

  Anderson, Katie L ^a   Modiano, Jaime F ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adaptive immunity; Antibodies; Fas ligand; Immunization; T lymphocytes; Virotherapy

Indexed keywords

EID: 85001970249     PISSN: None     EISSN: 23067381     Source Type: Journal    
DOI: 10.3390/vetsci2040363     Document Type: Review

References (105)

1. Couzin-Frankel, J. Cancer immunotherapy. Science 2013, 342, 1432-1433
2. Elert, E. Calling cells to arms. Nature 2013, 504, S2-S3
3. Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. Nature 2011, 480, 480-489
4. Makkouk, A.; Weiner, G.J. Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 2015, 75, 5-10
5. O'Connor, C.M.; Wilson-Robles, H. Developing T cell cancer immunotherapy in the dog with lymphoma. ILAR J. 2014, 55, 169-181
6. Vacchelli, E.; Aranda, F.; Eggermont, A.; Galon, J.; Sautes-Fridman, C.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014, 3, doi:10.4161/onci.27048
7. Sliwkowski, M.X.; Mellman, I. Antibody therapeutics in cancer. Science 2013, 341, 1192-1198
8. Singer, J.; Fazekas, J.; Wang, W.; Weichselbaumer, M.; Matz, M.; Mader, A.; Steinfellner, W.; Meitz, S.; Mechtcheriakova, D.; Sobanov, Y.; et al. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol. Cancer Ther. 2014, 13, 1777-1790
9. Ito, D.; Brewer, S.; Modiano, J.F.; Beall, M.J. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk Lymphoma 2015, 56, 219-225
10. Manches, O.; Lui, G.; Molens, J.P.; Sotto, J.J.; Chaperot, L.; Plumas, J. Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells. Cytotherapy 2008, 10, 642-649
11. Deligne, C.; Metidji, A.; Fridman, W.H.; Teillaud, J.L. Anti-CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T cell expansion in mice. Leukemia 2015, 29, 947-957
12. Ito, D.; Efe, J.; Rue, S. A Chimeric (Canine) Anti-CD20 Monoclonal Antibody is Effective in A Xenograft Model of Canine Lymphoma; Melnick, A., Staudt, L.M., Weinstock, D., Eds.; American Society of Hematology: Colorado Springs, CO, USA, 2014; p. 102
13. Beall, M.J. Canine Anti-CD20 Antibodies. US20110091483 A1, 21 April 2011. Available online: http://www.google.com/patents/US20110091483 (accessed on 16 October 2015)
14. Rue, S.; Eckleman, B.; Deveraux, Q.; Nasoff, N. Monoclonal Antibodies and Methods of Use. WO 2013063186 A1, 2013. Available online: https://data.epo.org/gpi/EP2771694A4-MONOCLONAL-ANTIBODIES-AND-METHODS-OF-USE ( accessed on 16 October 2015)
15. Hansen, G. Monoclonal Antibodies. US20110217298 A1, 2012. Available online: http://www.google.com/patents/US20110217298 (accessed on 16 October 2015)
16. Ogilvie, G. Treatment of Canine B-Cell Lymphoma with Chemotherapy and A Canine Anti-CD20 Monoclonal Antibody: A Prospective Double-Blind, Randomized, Placebo-Controlled Study. In Proceedings of the Veterinary Cancer Society Annual Meeting, St. Louis, MO, USA, 10 October 2014
17. Chao, M.P.; Alizadeh, A.A.; Tang, C.; Myklebust, J.H.; Varghese, B.; Gill, S.; Jan, M.; Cha, A.C.; Chan, C.K.; Tan, B.T.; et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell 2010, 142, 699-713
18. Majeti, R.; Chao, M.P.; Alizadeh, A.A.; Pang, W.W.; Jaiswal, S.; Gibbs, K.D., Jr.; van Rooijen, N.; Weissman, I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138, 286-299
19. Aratana Therapeutics Announces Conditional Approval of Second Canine-Specific Antibody Therapy. In AT-005 Marks Aratana's First Commercial Opportunity in T-Cell Canine Lymphoma; PR Newswire: Kansas City, MO, USA, 2014. Available online: http://www.aratana.com/ (accessed on 16 October 2015)
20. Trivedi, S.; Jie, H.B.; Ferris, R.L. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin. Oncol. 2014, 41, 678-684
21. Winston, J.; Craft, D.M.; Scase, T.J.; Bergman, P.J. Immunohistochemical detection of Her-2/neu expression in spontaneous feline mammary tumours. Vet. Comp. Oncol. 2005, 3, 8-15
22. Cannon, C. Cats, cancer and comparative oncology. Vet. Sci. 2015, 2, 111-126
23. Michishita, M.; Uto, T.; Nakazawa, R.; Yoshimura, H.; Ogihara, K.; Naya, Y.; Tajima, T.; Azakami, D.; Kishikawa, S.; Arai, T.; et al. Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma. J. Pharmacol. Sci. 2013, 121, 339-342
24. Scharf, V.F.; Farese, J.P.; Coomer, A.R.; Milner, R.J.; Taylor, D.P.; Salute, A.R.; Chang, M.N.; Neal, D.; Siemann, D.W. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. Am. J. Vet. Res. 2013, 74, 771-778
25. Huang, Y.; Goel, S.; Duda, D.G.; Fukumura, D.; Jain, R.K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013, 73, 2943-2948
26. Huang, Y.; Yuan, J.; Righi, E.; Kamoun, W.S.; Ancukiewicz, M.; Nezivar, J.; Santosuosso, M.; Martin, J.D.; Martin, M.R.; Vianello, F.; et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. PNAS 2012, 109, 17561-17566
27. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205-214
28. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56-61
29. Weintraub, K. Releasing the brakes. Nature 2013, 504, S6-S8
30. Lesokhin, A.M.; Callahan, M.K.; Postow, M.A.; Wolchok, J.D. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 2015, 7, 1-12
31. Maekawa, N.; Konnai, S.; Ikebuchi, R.; Okagawa, T.; Adachi, M.; Takagi, S.; Kagawa, Y.; Nakajima, C.; Suzuki, Y.; Murata, S.; et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS ONE 2014, 9, doi:10.1371/journal.pone.0098415
32. Shin, I.S.; Choi, E.W.; Chung, J.Y.; Hwang, C.Y.; Lee, C.W.; Youn, H.Y. Cloning, expression and bioassay of canine CTLA4-Ig. Vet. Immunol. Immunopathol. 2007, 118, 12-18
33. Graves, S.S.; Stone, D.; Loretz, C.; Peterson, L.; McCune, J.S.; Mielcarek, M.; Storb, R. Establishment of long-term tolerance to srbc in dogs by recombinant canine CTLA4-Ig. Transplantation 2009, 88, 317-322
34. Kontermann, R.E.; Brinkmann, U. Bispecific antibodies. Drug Discov. Today 2015, 20, 838-847
35. Huehls, A.; Coupet, T.; Sentman, C. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 2015, 93, 290-296
36. Knorr, D.A.; Bachanova, V.; Verneris, M.R.; Miller, J.S. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 2014, 26, 161-172
37. Mack, F.; Ritchie, M.; Sapra, P. The next generation of antibody drug conjugates. Semin. Oncol. 2014, 41, 637-652
38. Peters, C.; Brown, S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 2015, 35, doi:10.1042/BSR20150089
39. Bethge, W.A.; Wilbur, D.S.; Storb, R.; Hamlin, D.K.; Santos, E.B.; Brechbiel, M.W.; Sandmaier, B.M. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation study. Transplantation 2004, 78, 352-359
40. Bethge, W.A.; Wilbur, D.S.; Sandmaier, B.M. Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leuk Lymphoma 2006, 47, 1205-1214
41. Burtner, C.; Chandrasekaran, D.; Santos, E.; Beard, B.; Adair, J.; Hamlin, D.; Wilbur, D.S.; Sandmaier, B.; Kiem, H.P. 211 astatine-conjugated monoclonal CD45 antibody-based nonmyeloablative conditioning for stem cell gene therapy. Hum. Gene Ther. 2015, 26, 399-406
42. Modiano, J.F.; Lamerato-Kozicki, A.R.; Jubala, C.M.; Coffey, D.; Borakove, M.; Schaack, J.; Bellgrau, D. Fas ligand gene transfer for cancer therapy. Cancer Ther. 2004, 2, 561-570
43. Modiano, J.F.; Bellgrau, D.; Cutter, G.R.; Lana, S.E.; Ehrhart, N.P.; Ehrhart, E.; Wilke, V.L.; Charles, J.B.; Munson, S.; Scott, M.C.; et al. Inflammation, apoptosis, and necrosis induced by neoadjuvant Fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol. Ther. 2012, 20, 2234-2243
44. Duke, R.C.; Newell, E.; Schleicher, M.; Meech, S.J.; Bellgrau, D. Transplantation of cells and tissues expressing Fas ligand. Transplant. Proc. 1999, 31, 1479-1481
45. Seino, K.; Kayagaki, N.; Okumura, K.; Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med. 1997, 3, 165-170
46. Hohlbaum, A.M.; Gregory, M.S.; Ju, S.T.; Marshak-Rothstein, A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 2001, 167, 6217-6224
47. Shimizu, M.; Fontana, A.; Takeda, Y.; Yagita, H.; Yoshimoto, T.; Matsuzawa, A. Induction of antitumor immunity with Fas/APO-1 ligand (CD95l)-transfected neuroblastoma neuro-2a cells. J. Immunol. 1999, 162, 7350-7357
48. Arai, H.; Gordon, D.; Nabel, E.G.; Nabel, G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. 1997, 94, 13862-13867
49. Simon, A.K.; Gallimore, A.; Jones, E.; Sawitzki, B.; Cerundolo, V.; Screaton, G.R. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2002, 2, 315-322
50. Weaver, C.T.; Harrington, L.E.; Mangan, P.R.; Gavrieli, M.; Murphy, K.M. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24, 677-688
51. Chen, A.; Liu, S.; Park, D.; Kang, Y.; Zheng, G. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res. 2007, 67, 1291-1298
52. Bianco, S.R.; Sun, J.; Fosmire, S.P.; Hance, K.; Padilla, M.L.; Ritt, M.G.; Getzy, D.M.; Duke, R.C.; Withrow, S.J.; Lana, S.; et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003, 10, 726-736
53. Hedlund, T.E.; Meech, S.J.; Srikanth, S.; Kraft, A.S.; Miller, G.J.; Schaack, J.; Duke, R. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999, 6, 175-182
54. Wood, L.M.; Paterson, Y. Attenuated Listeria monocytogenes: A powerful and versatile vector for the future of tumor immunotherapy. Front. Cell. Infect. Microbiol. 2014, 4, doi:10.3389/fcimb.2014.00051
55. Thamm, D.H.; Kurzman, I.D.; King, I.; Li, Z.; Sznol, M.; Dubielzig, R.R.; Vail, D.M.; MacEwen, E.G. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: Phase I evaluation. Clin. Cancer Res. 2005, 11, 4827-4834
56. Saltzman, D.A. Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells. Expert Opin. Biol. Ther. 2005, 5, 443-449
57. Sorenson, B.S.; Banton, K.L.; Frykman, N.L.; Leonard, A.S.; Saltzman, D.A. Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. Clin. Orthop. Relat. Res. 2008, 466, 1285-1291
58. Fritz, S.E.; Henson, M.; Greengard, E.; Winter, A.L.; Stuebner, K.M.; Yoon, U.; Wilke, V.L.; Borgatti, A.; Augustin, L.B.; Modiano, J.F.; et al. A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar typhimurium for canine osteosarcoma. J. Vet. Med. Sci. 2015, submitted
59. Gnanandarajah, J.S.; Ndikuyeze, G.; Engiles, J.B.; Wallecha, A.; Mason, N. A recombinant Her2/neu expressing Listeria monocytogenes (lm-llo) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma-A phase I clinical trial. J. ImmunoTher. Cancer 2014, 2, doi:10.1186/2051-1426-2-S3-P55
60. Pol, J.; Bloy, N.; Obrist, F.; Eggermont, A.; Galon, J.; Cremer, I.; Erbs, P.; Limacher, J.M.; Preville, X.; Zitvogel, L.; et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2014, 3, doi:10.4161/onci.28694
61. Lichty, B.D.; Breitbach, C.J.; Stojdl, D.F.; Bell, J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 2014, 14, 559-567
62. Gentschev, I.; Patil, S.S.; Petrov, I.; Cappello, J.; Adelfinger, M.; Szalay, A.A. Oncolytic virotherapy of canine and feline cancer. Viruses 2014, 6, 2122-2137
63. Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98, 298-300
64. Breitbach, C.J.; Paterson, J.M.; Lemay, C.G.; Falls, T.J.; McGuire, A.; Parato, K.A.; Stojdl, D.F.; Daneshmand, M.; Speth, K.; Kirn, D.; et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 2007, 15, 1686-1693
65. Westberg, S.; Sadeghi, A.; Svensson, E.; Segall, T.; Dimopoulou, M.; Korsgren, O.; Hemminki, A.; Loskog, A.S.; Tötterman, T.H.; von Euler, H. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J. Immunother. 2013, 36, 350-358
66. Siddiqui, F.; Li, C.Y.; Larue, S.M.; Poulson, J.M.; Avery, P.R.; Pruitt, A.F.; Zhang, X.; Ullrich, R.L.; Thrall, D.E.; Dewhirst, M.W.; et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol. Cancer Ther. 2007, 6, 380-389
67. Jourdier, T.M.; Moste, C.; Bonnet, M.C.; Delisle, F.; Tafani, J.P.; Devauchelle, P.; Tartaglia, J.; Moingeon, P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL-2). Gene Ther. 2003, 10, 2126-2132
68. LeBlanc, A.K.; Naik, S.; Galyon, G.D.; Jenks, N.; Steele, M.; Peng, K.W.; Federspiel, M.J.; Donnell, R.; Russell, S.J. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum. Gene Ther. Clin. Dev. 2013, 24, 174-181
69. Bergman, P.J. Anticancer vaccines. Vet. Clin. North Am. Small Anim. Pract. 2007, 37, 1111-1119
70. Kissick, H.T.; Sanda, M.G. The role of active vaccination in cancer immunotherapy: Lessons from clinical trials. Curr. Opin. Immunol. 2015, 35, 15-22
71. Mulders, P.F.; de Santis, M.; Powles, T.; Fizazi, K. Targeted treatment of metastatic castration-resistant prostate cancer with Sipuleucel-T immunotherapy. Cancer Immunol. Immunother. 2015, 64, 655-663
72. Bergman, P.J.; McKnight, J.; Novosad, A.; Charney, S.; Farrelly, J.; Craft, D.M.; Wulderk, M.; Jeffers, Y.; Sadelain, M.; Hohenhaus, A.E.; et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clin. Cancer Res. 2003, 9, 1284-1290
73. Bergman, P.J.; Camps-Palau, M.A.; McKnight, J.A.; Leibman, N.F.; Craft, D.M.; Leung, C.; Liao, J.; Riviere, I.; Sadelain, M.; Hohenhaus, A.E.; et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 2006, 24, 4582-4585
74. Grosenbaugh, D.A.; Leard, A.T.; Bergman, P.J.; Klein, M.K.; Meleo, K.; Susaneck, S.; Hess, P.R.; Jankowski, M.K.; Jones, P.D.; Leibman, N.F.; et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am. J. Vet. Res. 2011, 72, 1631-1638
75. Ottnod, J.M.; Smedley, R.C.; Walshaw, R.; Hauptman, J.G.; Kiupel, M.; Obradovich, J.E. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet. Comp. Oncol. 2013, 11, 219-229
76. Liao, J.; Gregor, P.; Wolchok, J.D.; Orlandi, F.; Craft, D.M.; Leung, C.; Houghton, A.N.; Bergman, P.J. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunol. 2006, 6, 1-17
77. Vail, D.M. Levels of evidence in canine oncology trials-A case in point. Vet. Comp. Oncol. 2013, 11, 167-168
78. Peruzzi, D.; Gavazza, A.; Mesiti, G.; Lubas, G.; Scarselli, E.; Conforti, A.; Bendtsen, C.; Ciliberto, G.; La Monica, N.; Aurisicchio, L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 2010, 18, 1559-1567
79. Peruzzi, D.; Mesiti, G.; Ciliberto, G.; La Monica, N.; Aurisicchio, L. Telomerase and Her-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010, 28, 1201-1208
80. Gavazza, A.; Lubas, G.; Fridman, A.; Peruzzi, D.; Impellizeri, J.A.; Luberto, L.; Marra, E.; Roscilli, G.; Ciliberto, G.; Aurisicchio, L. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum. Gene Ther. 2013, 24, 728-738
81. Andersen, B.M.; Pluhar, G.E.; Seiler, C.E.; Goulart, M.R.; SantaCruz, K.S.; Schutten, M.M.; Meints, J.P.; O'Sullivan, M.G.; Bentley, R.T.; Packer, R.A.; et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res. 2013, 73, 2987-2997
82. Gyorffy, S.; Rodriguez-Lecompte, J.C.; Woods, P.; Foley, R.; Kruth, S.; Liaw, P.C.Y.; Gauldie, J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. Vet. Intern. Med. 2005, 19, 56-63
83. Sorenmo, K.U.; Krick, E.; Coughlin, C.M.; Overley, B.; Gregor, T.P.; Vonderheide, R.H.; Mason, N.J. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with Non-Hodgkin's lymphoma. PLoS ONE 2011, 6, doi:10.1371/journal.pone.0024167
84. Gabai, V.; Venanzi, F.M.; Bagashova, E.; Rud, O.; Mariotti, F.; Vullo, C.; Catone, G.; Sherman, M.Y.; Concetti, A.; Chursov, A.; et al. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 2015, 5, 12803-12810
85. Heinzerling, L.M.; Feige, K.; Rieder, S.; Akens, M.K.; Dummer, R.; Stranzinger, G.; Moelling, K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J. Mol. Med. 2001, 78, 692-702
86. Muller, J.-M.V.; Feige, K.; Wunderlin, P.; Hodl, A.; Meli, M.L.; Seltenhammer, M.; Grest, P.; Nicolson, L.; Schelling, C.; Heinzerling, L.M. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J. Immunother. 2011, 34, 58-64
87. Glikin, G.C.; Finocchiaro, L.M. Clinical trials of immunogene therapy for spontaneous tumors in companion animals. Sci. World J. 2014, 2014, doi:10.1155/2014/718520
88. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.; Borresen-Dale, A.L.; et al. Signatures of mutational processes in human cancer. Nature 2013, 500, 415-421
89. Maus, M.V.; Grupp, S.A.; Porter, D.L.; June, C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123, 2625-2635
90. Rosenberg, S.A.; Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348, 62-68
91. June, C.H.; Riddell, S.R.; Schumacher, T.N. Adoptive cellular therapy: A race to the fnish line. Sci. Transl. Med. 2015, 7, 1-8
92. O'Connor, C.M.; Sheppard, S.; Hartline, C.A.; Huls, H.; Johnson, M.; Palla, S.L.; Maiti, S.; Ma, W.; Davis, R.E.; Craig, S.; et al. Adoptive T-cell therapy improves treatment of canine Non-Hodgkin lymphoma post chemotherapy. Sci. Rep. 2012, 2, doi:10.1038/srep00249
93. Mata, M.; Vera, J.F.; Gerken, C.; Rooney, C.M.; Miller, T.; Pfent, C.; Wang, L.L.; Wilson-Robles, H.M.; Gottschalk, S. Toward immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. J. Immunother. 2014, 37, 407-415
94. Michael, H.T.; Ito, D.; McCullar, V.; Zhang, B.; Miller, J.S.; Modiano, J.F. Isolation and characterization of canine natural killer cells. Vet. Immunol. Immunopathol. 2013, 155, 211-217
95. Shin, D.J.; Lee, S.H.; Park, J.Y.; Kim, J.S.; Lee, J.J.; Suh, G.H.; Lee, Y.K.; Cho, D.; Kim, S.K. Interleukin-21 induces proliferation and modulates receptor expression and effector function in canine natural killer cells. Vet. Immunol. Immunopathol. 2015, 165, 22-33
96. Lee, S.H.; Shin, D.J.; Kim, S.K. Generation of recombinant canine interleukin-15 and evaluation of its effects on the proliferation and function of canine NK cells. Vet. Immunol. Immunopathol. 2015, 165, 1-13
97. Burkholder, B.; Huang, R.Y.; Burgess, R.; Luo, S.; Jones, V.S.; Zhang, W.; Lv, Z.Q.; Gao, C.Y.; Wang, B.L.; Zhang, Y.M.; et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 2014, 1845, 182-201
98. Twyman-Saint Victor, C.; Rech, A.J.; Maity, A.; Rengan, R.; Pauken, K.E.; Stelekati, E.; Benci, J.L.; Xu, B.; Dada, H.; Odorizzi, P.M.; et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520, 373-377
99. Alizadeh, D.; Trad, M.; Hanke, N.T.; Larmonier, C.B.; Janikashvili, N.; Bonnotte, B.; Katsanis, E.; Larmonier, N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer. Cancer Res. 2014, 74, 104-118
100. Hannesdottir, L.; Tymoszuk, P.; Parajuli, N.; Wasmer, M.H.; Philipp, S.; Daschil, N.; Datta, S.; Koller, J.B.; Tripp, C.H.; Stoitzner, P.; et al. Lapatinib and doxorubicin enhance the STAT1-dependent antitumor immune response. Eur. J. Immunol. 2013, 43, 2718-2729
101. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G.M.; Apetoh, L.; Perfettini, J.L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13, 54-61
102. Maus, M.V.; Haas, A.R.; Beatty, G.L.; Albelda, S.M.; Levine, B.L.; Liu, X.; Zhao, Y.; Kalos, M.; June, C.H. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 2013, 1, 26-31
103. Mirsoian, A.; Bouchlaka, M.N.; Sckisel, G.D.; Chen, M.; Pai, C.C.; Maverakis, E.; Spencer, R.G.; Fishbein, K.W.; Siddiqui, S.; Monjazeb, A.M.; et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 2014, 211, 2373-2383
104. Rosinski, S.L.; Storb, R.; Strong, R.K.; Sale, G.E.; Stone, D.M.; Gewe, M.M.; Friend, D.J.; Abrams, V.K.; Randolph-Habecker, J.; Graves, S.S. Anti-CD28 antibody-initiated cytokine storm in canines. Transplant. Direct 2015, 1, doi:10.1097/TXD.0000000000000516
105. Wolchok, J.D.; Hoos, A.; O'Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412-7420